Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

Sara Caporuscio, Roberto Ieraci, Guido Valesini, Raffaela Teloni, Sabrina Mariotti, Francesca Romana Spinelli, Claudia Ferlito, Simonetta Salemi, Andrea Picchianti Diamanti, Giorgia Meneguzzi, Milica Markovic, Mayla Sgrulletti, Christina von Hunolstein, Luisa Ralli, Antonietta Pinto, Gerardo Salerno, Marco Canzoni, Maria Laura Sorgi, Bruno Laganà, Roberta Di RosaRoberto Nisini, Raffaele D'Amelio

Research output: Contribution to journalArticle

Abstract

Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalClinical Immunology
Volume195
DOIs
Publication statusPublished - Oct 1 2018

Keywords

  • 13-valent pneumococcal conjugate vaccine
  • Antibody persistence
  • Immunogenicity
  • Immunosuppressive therapy
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy'. Together they form a unique fingerprint.

  • Cite this

    Caporuscio, S., Ieraci, R., Valesini, G., Teloni, R., Mariotti, S., Spinelli, F. R., Ferlito, C., Salemi, S., Picchianti Diamanti, A., Meneguzzi, G., Markovic, M., Sgrulletti, M., von Hunolstein, C., Ralli, L., Pinto, A., Salerno, G., Canzoni, M., Sorgi, M. L., Laganà, B., ... D'Amelio, R. (2018). Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clinical Immunology, 195, 18-27. https://doi.org/10.1016/j.clim.2018.07.010